|
Home
What is
Hepatitis
How is it
Transmitted
Long Term
Prognosis
Complications of
HCV
Liver
Biopsy
Treatment Info
(Interferon, Herbal, etc)
Lab Tests (PCR,
Genotype,etc.)
Nutrition
& Alternative Info
Patient
Information (Support Groups, Doctor Listing,
etc)
Related
Webpages
Transplant
Info
Site
Search
HCV
Webrings
My
guestbookbook
Site
Awards
FAQ &
Disclaimers
|
DIFFERENTIAL BIOLOGICAL PROPERTIES OF CONSENSUS INTERFERON
COMPARED TO INTERFERON [alpha] 2 MAY LEAD TO DIFFERENTIAL CLINICAL
RESPONSES IN THE TREATMENT OF CHRONIC HCV INFECTION
LM Blatt, SB Klein, MW Taylor and M Tong, Amgen Inc.,
Boulder, CO, Indiana University, Bloomington, IN and Huntington
Memorial Hospital, Pasadena, CA
Type I interferons (IFN) are a class of natural cytokines that
includes a family of greater than 25 IFN[alpha]'s as well as
IFN-ß, and IFN-[omega]. Characterization of type 1 IFN's
demonstrates many differences in the primary sequence of these
molecules, implying an evolutionary divergence in biological
activity. Although type 1 IFN's have shown success in the treatment
of chronic HCV infection, most clinical use of type interferon has
been limited to the alpha 2 subtype. The mechanism of action of
type 1 IFN in the treatment of chronic HCV infection has yet to be
elucidated but may involve the antiviral, antiproliferative,
immunomodulatory, and cytokine/gene regulation activities of these
pleotropic molecules. In order to assess the potential for clinical
differences in the treatment of chronic HCV infection between IFN
[alpha] 2 and CIFN, a novel non-naturally occurring type 1 IFN, we
examined the in vitro antiviral, antiproliferative, NK cell
activation activity, cytokine induction and interferon stimulated
gene-induction activity of these two different IFN's. For all
comparisons, when compared on a equal mass basis, CIFN displayed
between five and one hundred times higher activity. In order to
elucidate the potential mechanism for the higher activity of CIFN
compared to IFN [alpha] 2, we studied the receptor binding
characteristics of the two IFN's by Scatchard analysis. The results
of the Scatchard analysis demonstrated a 10-fold higher binding
affinity for the IFN type 1 receptor for CIFN compared to
IFN-[alpha] 2. These unique biological properties of CIFN may lead
to a favorable clinical benefit in the treatment of chronic HCV
infection for CIFN when compared to the IFN [alpha] 2 due to the
increased biologic effects and higher receptor affinity of this new
molecule.
This research was funded by Amgen Inc., Boulder, CO.
Source: American Association for the Study of Liver Diseases
- 1996 Annual Meeting
Home | What is HCV | Transmission |
Future |
Complications |
Biopsy |
Treatment
| Lab |
Nutrition |
Patient |
Links | Transplant |
Webrings |
guestbookbook |
Awards |
FAQ
|
|